JP2022549156A5 - - Google Patents

Info

Publication number
JP2022549156A5
JP2022549156A5 JP2022517410A JP2022517410A JP2022549156A5 JP 2022549156 A5 JP2022549156 A5 JP 2022549156A5 JP 2022517410 A JP2022517410 A JP 2022517410A JP 2022517410 A JP2022517410 A JP 2022517410A JP 2022549156 A5 JP2022549156 A5 JP 2022549156A5
Authority
JP
Japan
Prior art keywords
cancer
seq
dkk1
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022517410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549156A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/051550 external-priority patent/WO2021055789A1/en
Publication of JP2022549156A publication Critical patent/JP2022549156A/ja
Publication of JP2022549156A5 publication Critical patent/JP2022549156A5/ja
Pending legal-status Critical Current

Links

JP2022517410A 2019-09-19 2020-09-18 癌を治療するためのｄｋｋ－１阻害剤の使用 Pending JP2022549156A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902857P 2019-09-19 2019-09-19
US62/902,857 2019-09-19
PCT/US2020/051550 WO2021055789A1 (en) 2019-09-19 2020-09-18 Use of dkk-1 inhibitors for treating cancer

Publications (2)

Publication Number Publication Date
JP2022549156A JP2022549156A (ja) 2022-11-24
JP2022549156A5 true JP2022549156A5 (https=) 2023-09-11

Family

ID=72670867

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022517410A Pending JP2022549156A (ja) 2019-09-19 2020-09-18 癌を治療するためのｄｋｋ－１阻害剤の使用

Country Status (11)

Country Link
US (1) US20220381786A1 (https=)
EP (1) EP4031175A1 (https=)
JP (1) JP2022549156A (https=)
KR (1) KR102883931B1 (https=)
CN (1) CN114423459A (https=)
AU (1) AU2020348457A1 (https=)
BR (1) BR112022004851A2 (https=)
CA (1) CA3151228A1 (https=)
IL (1) IL291424A (https=)
MX (1) MX2022003396A (https=)
WO (1) WO2021055789A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3041325A1 (en) 2016-10-26 2018-05-03 Leap Therapeutics, Inc. Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
WO2023039249A1 (en) * 2021-09-10 2023-03-16 Leap Therapeutics, Inc. Combination therapy
IL318268A (en) * 2022-07-12 2025-03-01 Leap Therapeutics Inc Combined treatment

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1735350A (en) 1921-07-02 1929-11-12 United Shoe Machinery Corp Machine for securing together two or more pieces of sheet material
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5475120A (en) 1990-11-02 1995-12-12 University Of Florida Method for the isolation and purification of taxol and its natural analogues
US5194635A (en) 1991-03-18 1993-03-16 Virginia Tech Intellectual Properties, Inc. Rearranged taxol compounds and method of using in testing of in vivo activity
US5488116A (en) 1992-03-30 1996-01-30 Sloan-Kettering Institute For Cancer Research Total synthesis of taxol and analogues thereof
US5416225A (en) 1992-03-30 1995-05-16 Sloan-Kettering Institute For Cancer Research Total synthesis of taxol
US5440056A (en) 1992-04-17 1995-08-08 Abbott Laboratories 9-deoxotaxane compounds
CA2130578A1 (en) 1992-04-17 1993-10-28 Geewananda P. Gunawardana Taxol derivatives
US5461169A (en) 1992-06-23 1995-10-24 The Scripps Research Institute Total synthesis of taxol and taxol analogs
US5440057A (en) 1993-08-20 1995-08-08 The Scripps Research Institute Access to taxol analogs
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5478854A (en) 1992-10-01 1995-12-26 Bristol-Myers Squibb Company Deoxy taxols
US5411984A (en) 1992-10-16 1995-05-02 Virginia Tech Intellectual Properties, Inc. Water soluble analogs and prodrugs of taxol
WO1994013827A1 (en) 1992-12-07 1994-06-23 Michigan State University PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp
US5468769A (en) 1993-07-15 1995-11-21 Abbott Laboratories Paclitaxel derivatives
FR2707642B1 (fr) 1993-07-16 1995-10-13 Electricite De France Dérivés de polyéthers et d'hétérocycles pentacycliques, leurs polymères et leurs applications, notamment à la complexation d'ions métalliques.
US5405972A (en) 1993-07-20 1995-04-11 Florida State University Synthetic process for the preparation of taxol and other tricyclic and tetracyclic taxanes
US5565478A (en) 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5508447A (en) 1994-05-24 1996-04-16 Board Of Regents, The University Of Texas System Short synthetic route to taxol and taxol derivatives
US5489589A (en) 1994-12-07 1996-02-06 Bristol-Myers Squibb Company Amino acid derivatives of paclitaxel
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
WO2009028158A1 (en) * 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
AR075989A1 (es) 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
CA3041325A1 (en) * 2016-10-26 2018-05-03 Leap Therapeutics, Inc. Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
EP4061419A1 (en) * 2019-11-22 2022-09-28 Leap Therapeutics, Inc. Methods of treating cancer using dkk-1-inhibitors

Similar Documents

Publication Publication Date Title
JP2022191301A5 (https=)
JP2024016177A5 (https=)
RU2019111722A (ru) Антитела против siglec-15 и способы их применения
JP2020099324A5 (https=)
JP2020536109A5 (https=)
RU2018123717A (ru) Комбинированные лечения, их применения и способы
JP2021513540A5 (https=)
JP2020518600A5 (https=)
JP2025131696A5 (https=)
RU2018146886A (ru) Пути терапевтического применения ингибитора c-raf
JP2023055904A5 (https=)
JP2013542194A5 (https=)
FI3810281T3 (fi) Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla
RU2012156938A (ru) Антитела против gdf8 человека
JP2021527640A5 (https=)
RU2019112029A (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
RU2014139552A (ru) Человеческие антитела к токсинам clostridium difficile
JP2018508462A5 (https=)
RU2014148502A (ru) Человеческие антитела к fel d1 и способы их применения
JP2013520442A5 (https=)
JP2022549156A5 (https=)
JP2021514945A5 (https=)
RU2014143784A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря
JP2021528423A5 (https=)
ME02798B (me) Protutijela protiv dkk-1"